Bristol-Myers Squibb was founded in 1858 and has grown to be one of today's leading global pharmaceutical companies.

GST-HG141, administered orally at 50 and 100 mg BID, was safe, well-tolerated, and highly effective in suppressing residual HBV DNA and pgRNA levels in CHB patients with LLV. These results support the ...